OncoMatch/Clinical Trials/NCT05918445

PM8002 in the Treatment of Patients With Advanced Solid Tumors

Is NCT05918445 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies PM8002 for malignant neoplasm.

Phase 1/2RecruitingBiotheus Inc.NCT05918445Data as of May 2026

Treatment: PM8002 — This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of PM8002, a PD-L1/VEGF bispecific antibody, as a single agent in adult subjects with advanced solid tumors.

Check if I qualify

Extracted eligibility criteria

Cancer type

Tumor Agnostic

Performance status

ECOG 0–1(Restricted strenuous activity)

Lab requirements

Blood counts

Adequate organ function

Kidney function

Adequate organ function

Liver function

Adequate organ function

Adequate organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify